Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Overview of ER+/HER2- Metastatic Breast Cancer (mBC)

January 30th 2023

Paolo Tarantino, MD, provides an overview of ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- mBC), highlighting the prevalence, patient populations, and the typical prognosis.

Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

January 30th 2023

The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.

De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

January 30th 2023

Debu Tripathy, MD, details when he utilizes a treatment de-escalation approach in his patients with HER2+ early breast cancer.

Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer

January 30th 2023

Jose Pablo Leone, MD, discusses the distinguishing features of male breast cancer, explains the benefits and limitations of current treatments, and emphasizes the importance of raising awareness about this breast cancer subset to propel further research.

Overview of Treatment Options for Patients with Breast Cancer

January 30th 2023

Breast cancer experts provide a comprehensive overview of treatment options and clinical trials in breast cancer.

Patient Profile 2: A 62-Year-Old Woman with Metastatic HR+ Breast Cancer

January 30th 2023

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, analyze a patient case of a 62-year-old woman with metastatic HR+ breast cancer.

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 27th 2023

The FDA has approved elacestrant (Orserdu) for the treatment of postmenopausal women or adult men with estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy.

Accuracy of Sentinel Lymph Node Biopsies Are Vital to Inform Treatment Decisions in Breast Cancer

January 27th 2023

The evolving treatment landscape across breast cancer has escalated the need for the accuracy of sentinel lymph node biopsies following treatment with neoadjuvant chemotherapy to correctly inform subsequent treatment decisions for patients.

A Wealth of Clinical Trials Expands Potential Breast Cancer Treatment Options

January 26th 2023

Joyce O’Shaughnessy, MD, highlights key data from the 2022 San Antonio Breast Cancer Symposium, explains how trastuzumab deruxtecan and CDK4/6 inhibitors are altering the treatment landscape, and discusses novel data on steroid receptor expression in triple-negative breast cancer.

Dr. Rotroff on Biomarkers Associated With the Risk of Peripheral Neuropathy in Breast Cancer

January 25th 2023

Daniel Rotroff, PhD, discusses the investigation of biomarkers that could help identify patients with breast cancer who are at risk for developing chemotherapy-induced peripheral neuropathy.

Dr. Hunter on the Role of 18F-FES-PET Imaging in Triple-Positive Breast Cancer

January 25th 2023

Natasha B Hunter, MD, discusses the utility of 18F-Fluoroestradiol PET imaging for patients with estrogen receptor–positive and HER2-positive breast cancer.

Dr. Vicini on the Potential Utility of the DCISionRT Test in HER2+ DCIS of the Breast

January 25th 2023

Frank A. Vicini, MD, discusses the potential utility of using the DCISionRT test to determine treatment benefit in the phase 3 NRG-NSABP-B43 trial in HER2-positive ductal carcinoma in situ of the breast.

Dr. Stanton on Improving Responses to Immunotherapy in Early-Stage HR+ Breast Cancer

January 25th 2023

Sasha Stanton, MD, discusses efforts to improve the responses to immunotherapy regimens in early-stage hormone receptor–positive breast cancer.

Key Takeaways from Clinical Trials of Trastuzumab Deruxtecan in Different Populations

January 25th 2023

Dr Krop leads a discussion of results from the DESTINY-Breast02 and DESTINY-Breast03 studies concerning the use of trastuzumab deruxtecan in patients with metastatic breast cancer.

Recent Updates for the Advanced HR+ Breast Cancer Setting

January 25th 2023

Charles E. Geyer, MD and Ian E. Krop, MD, PhD touch on recent advances in the metastatic HR+ breast cancer setting and evaluate PROTAC estrogen receptor (ER) degraders compared with other ER modulators.

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

Drs Goetz and Choong discuss the potential for adjuvant endocrine therapy omission in patients with estrogen receptor–positive breast cancer who have a pathologic complete response to neoadjuvant chemotherapy.

Novel Biomarker Tests Increase Accuracy of Breast and Lung Cancer Diagnoses

January 23rd 2023

Andrew McKenzie, PhD, discusses biomarkers to test for in breast and lung cancers, the value of multicancer early detection, and how biomarker testing can better direct targeted treatment across solid tumors.

Clinical Insights on the Use of Adjuvant Therapy Plus Abemaciclib in HR+ Breast Cancer

January 23rd 2023

Detailed clinical insights on the use of adjuvant therapy plus abemaciclib in patients with high-risk, early stage HR+ breast cancer.

Abemaciclib Plus Adjuvant Endocrine Therapy in Breast Cancer

January 23rd 2023

Using the monarchE trial as a benchmark, experts in oncology discuss the use of abemaciclib with adjuvant endocrine therapy in patients with high-risk, early stage HR+ breast cancer.

Dr. O’Shaughnessy on DESTINY-Breast02 and DESTINY-Breast03 in Metastatic HER2+ Breast Cancer

January 20th 2023

Joyce A. O’Shaughnessy, MD, discusses key data from the phase 3 DESTINY-Breast02 and DESTINY-Breast03 trials in metastatic HER2-positive breast cancer.